Skip to Content
Merck
  • Anti-Depressant Fluoxetine Reveals its Therapeutic Effect Via Astrocytes.

Anti-Depressant Fluoxetine Reveals its Therapeutic Effect Via Astrocytes.

EBioMedicine (2018-06-12)
Manao Kinoshita, Yuri Hirayama, Kayoko Fujishita, Keisuke Shibata, Youichi Shinozaki, Eiji Shigetomi, Akiko Takeda, Ha Pham Ngoc Le, Hideaki Hayashi, Miki Hiasa, Yoshinori Moriyama, Kazuhiro Ikenaka, Kenji F Tanaka, Schuichi Koizumi
ABSTRACT

Although psychotropic drugs act on neurons and glial cells, how glia respond, and whether glial responses are involved in therapeutic effects are poorly understood. Here, we show that fluoxetine (FLX), an anti-depressant, mediates its anti-depressive effect by increasing the gliotransmission of ATP. FLX increased ATP exocytosis via vesicular nucleotide transporter (VNUT). FLX-induced anti-depressive behavior was decreased in astrocyte-selective VNUT-knockout mice or when VNUT was deleted in mice, but it was increased when astrocyte-selective VNUT was overexpressed in mice. This suggests that VNUT-dependent astrocytic ATP exocytosis has a critical role in the therapeutic effect of FLX. Released ATP and its metabolite adenosine act on P2Y11 and adenosine A2b receptors expressed by astrocytes, causing an increase in brain-derived neurotrophic factor in astrocytes. These findings suggest that in addition to neurons, FLX acts on astrocytes and mediates its therapeutic effects by increasing ATP gliotransmission.

MATERIALS
Product Number
Brand
Product Description

Roche
ATP Bioluminescence Assay Kit CLS II, sufficient for 800 assays (tubes), kit of 1 (2 components), suitable for detection
Sigma-Aldrich
Monoclonal Anti-β-Actin antibody produced in mouse, clone AC-74, ascites fluid
Sigma-Aldrich
W-7, Hydrochloride, A cell-permeable and reversible calmodulin antagonist that inhibits myosin light chain kinase (IC₅₀ = 51 µM) and Ca2+-calmodulin-dependent phosphodiesterase (IC₅₀ = 28 µM).
Sigma-Aldrich
MRS-1706, ≥98% (HPLC)
Sigma-Aldrich
MRS 2179 ammonium salt hydrate, ≥98% (HPLC)